One song can contain multitudes of inspiration, with some influences stronger than others. And indeed, The Who’s 1967 track “Pictures Of Lily” off Meaty Beaty Big And Bouncy is no exception.

Terence Flynn, an analyst at Morgan Stanley, recently reiterated an overweight (or "buy") rating on Eli Lilly stock along with a price target of $1,327. That suggests an upside of about 52% from its ...

Of course, Lilly isn't alone in this market -- it shares the space with Novo Nordisk, seller of blockbuster drugs Ozempic and Wegovy. And Lilly also faces the possibility of more competition down the ...

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact too. Lilly notified Rigel ...

Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up ...

Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the Big Pharma team up with Profluent to develop AI-designed recombinases to address diseases with severe unmet needs.

Eli Lilly LLY is set to release its first-quarter 2026 earnings report on April 30. Here’s Morningstar’s take on what to look for in Lilly’s earnings and the outlook for its stock. With its 3-star ...

April 27 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up ‌to $2.3 billion in cash, as the U.S. drugmaker looks to ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

April 28 (Reuters) - AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly (LLY.N), opens new tab worth up ‌to $2.25 billion to develop ...

Eli Lilly and Company (LLY) has seen its stock fall by more than 20% since peaking in mid-January and has not even participated in the latest stock market rally. That may be about to change, at least ...

Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a ...